A surge in deals and financings had the industry abuzz heading into this year’s J.P Morgan Healthcare Conference. But some ...

With the planned purchase, Boston Scientific will gain a portfolio of devices to remove clots from blood vessels.

Oxford, major contract manufacturer to cell and gene therapy companies, has already rejected multiple, unsolicited ...

The results build on evidence U.S. regulators found so compelling last year they proactively awarded J&J a new kind of drug review voucher.

Drugmaker CEOs see sales online channels as a budding opportunity, while some biotech investors told BioPharma Dive to expect ...

Four recent deals fueled more angst about China’s biotech progress, while Pfizer, Bristol Myers and Sarepta all worked to ...

As with the many other “most-favored-nation” deals between the White House and large pharmas, the agreement is short on ...

Startups raised $14.2 billion last year, the highest funding total since 2022. Health AI companies collected 54% of total ...

AbbVie is paying $650 million for a dual-targeting immunotherapy from China’s RemeGen. Elsewhere, Alnylam missed an earnings ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's ...

Regulatory and clinical roadblocks have set back its oral BTK inhibitor tolebrutinib, but the drug class still has many ...